Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis

James Douketis, Alberto Tosetto, Maura Marcucci, Trevor Baglin, Benilde Cosmi, Mary Cushman, Paul Kyrle, Daniela Poli, R Campbell Tait, Alfonso Iorio, James Douketis, Alberto Tosetto, Maura Marcucci, Trevor Baglin, Benilde Cosmi, Mary Cushman, Paul Kyrle, Daniela Poli, R Campbell Tait, Alfonso Iorio

Abstract

Objective: To determine the effect of sex on the risk of recurrent venous thromboembolism in all patients and in patients with venous thromboembolism that was unprovoked or provoked (by non-hormonal factors). Data source Comprehensive search of electronic databases (Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials) until July 2010, supplemented by review of conference abstracts and contact with content experts.

Study selection: Seven prospective studies investigating an association between D-dimer, measured after anticoagulation was stopped, and disease recurrence in patients with venous thromboembolism.

Data extraction: Patient level databases were obtained, transferred to a central database, checked, and completed with further information provided by authors.

Data synthesis: 2554 patients with a first venous thromboembolism had follow-up for a mean of 27.1 (SD 19.6) months. The one year incidence of recurrent venous thromboembolism was 5.3% (95% confidence interval 4.1% to 6.7%) in women and 9.5% (7.9% to 11.4%) in men, and the three year incidence of recurrence was 9.1% (7.3% to 11.3%) in women and 19.7% (16.5% to 23.4%) in men. Among patients with unprovoked venous thromboembolism, men had a higher risk of recurrence than did women (hazard ratio 2.2, 95% confidence interval 1.7 to 2.8). After adjustment for women with hormone associated initial venous thromboembolism, the risk of recurrence remained higher in men (hazard ratio 1.8, 1.4 to 2.5). In patients with provoked venous thromboembolism, occurring after exposure to a major risk factor, recurrence of disease did not differ between men and women (hazard ratio 1.2, 0.6 to 2.4). In women with hormone associated venous thromboembolism and no other risk factors, recurrence was lower than that in women with unprovoked venous thromboembolism and no previous hormone use (hazard ratio 0.5, 0.3 to 0.8).

Conclusion: In patients with a first unprovoked venous thromboembolism, men have a 2.2-fold higher risk of recurrent venous thromboembolism than do women, which remained 1.8-fold higher in men after adjustment for previous hormone associated venous thromboembolism in women. In patients with a first provoked venous thromboembolism, risk of recurrence does not differ between men and women with or without hormone associated venous thromboembolism. Indefinite anticoagulation may be given greater consideration in men than in women after a first venous thromboembolism.

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

References

    1. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005;93:298-305.
    1. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;23:21-9.
    1. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism: the Worcester Venous Thromboembolism Study. J Thromb Thrombolysis 2009;28:401-9.
    1. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-63.
    1. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-26.
    1. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.
    1. Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, et al. Venous thromboembolism and bleeding in a community setting: the Worcester Venous Thromboembolism Study. Thromb Haemost 2009;101:878-85.
    1. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1626 patients. Haematologica 2007;92:199-205.
    1. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
    1. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
    1. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 2006;368:371-8.
    1. Gjores JE. The incidence of venous thrombosis and its sequelae in certain districts in Sweden. Acta Chir Scand 1993;111(suppl 206):16-24S.
    1. Gillum RF. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. Am Heart J 1987;114:1262-4.
    1. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107(suppl 1):I9-16S.
    1. Lijfering WM, Veeger NJ, Middeldorp S, Hamulyák K, Prins MH, Büller HR, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009;114:2031-6.
    1. Pengo V, Prandoni P. Sex and anticoagulation in patients with idiopathic venous thromboembolism. Lancet 2006;368:342-3.
    1. Sud S, Douketis J. The devil is in the details . . . or not? A primer on individual patient data meta-analysis. Ann Intern Med 2009;151:JC1-3.
    1. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism. J Thromb Haemost 2009;7(suppl 2):OC-TH-004S.
    1. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008;149:481-90.
    1. Douketis JD, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess risk for recurrence after unprovoked venous thromboembolism. Ann Intern Med 2010;153:523-31.
    1. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian levels of evidence. BMC Med Res Methodol 2009;9:34.
    1. Altman DG. Systematic review of evaluations of prognostic variables. BMJ 2001;323:224-8.
    1. Wells G, Shea B, O’Connell D, Peterson J, Welch V. Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011. .
    1. Millet GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men. JAMA 2008;300:1674-84.
    1. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 2006;4:1208-14.
    1. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006;355:1780-9.
    1. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence? J Thromb Thrombolys 2008;25:37-44.
    1. Chan WS, Lee A, Spencer FA, Crowther M, Rodger M, Ramsay T, et al. Predicting deep venous thrombosis in pregnancy: out in “LEFt” field? Ann Intern Med 2009;151:85-92.
    1. Douketis JD, Ginsberg JS, Holbrook A, Crowther M, Duku EK, Burrows RF. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997;157:1522-30.
    1. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31.
    1. Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-8.
    1. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290:1071-4.
    1. Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of D-dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost 2008;6:708-10.
    1. Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost 2008;6:577-82.
    1. Tait R, Lowe GDO, McColl MD, McMahon AD, Robertson L, King L, et al. Predicting risk of recurrent venous thrombosis using a 5-point scoring system including fibrin D-dimer. J Thromb Haemost 2007;5(suppl 2):O-M-060S.
    1. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, et al, for the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis, N Engl J Med 2001;345:165-9.
    1. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25.
    1. Chang AM, Mumma B, Sease KL, Robey JL, Shofer FS, Hollander JE. Gender bias in cardiovascular testing persists after adjustment for presenting characteristics and cardiac risk. Acad Emerg Med 2007;14:599-605.
    1. Kahn SR, Joseph L, Abenhaim L, Leclerc JR. Clinical prediction of deep vein thrombosis in patients with leg symptoms. Thromb Haemost 1999;81:353-7.
    1. Oudega R, Moons KG, Hoes AW. Limited value of patient history and physical examination in diagnosing deep vein thrombosis in primary care. Fam Pract 2005;22:86-91.
    1. Beebe HG, Scissons RP, Salles-Cunha SX, Dosick SM, Whalen RC, Gale SS, et al. Gender bias in use of venous ultrasonography for diagnosis of deep venous thrombosis. J Vasc Surg 1995;22:538-42.
    1. Andreou RE, Koru-Sengul T, Linkins L, Bates SM, Ginsberg JS. Differences in clinical presentation of deep vein thrombosis in men and women. J Thromb Haemost 2008;6:1713-9.
    1. Douketis JD, Gu C, Piccioli A, Ghirarduzzi A, Pengo V, Prandoni P. The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost 2009;7:546-51.
    1. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: Duration of Anticoagulation Trial. N Engl J Med 2000;342:1953-8.
    1. Baron JA, Gridley G, Weiderpass E, Nyren G, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:1077-80.
    1. Sorensen HT, Mellemkjaer L, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep-venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73.
    1. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008;117:93-102.
    1. Steffen LM, Cushman M, Peacock JM, Heckbert SR, Jacobs DR Jr, Rosamond WD, et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2009;7:746-51.
    1. Borch KH, Braekken SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso Study. J Thromb Haemost 2009;7:739-45.
    1. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost 2007;5(suppl 1):270-5S.
    1. Ageno W, Dentali F, Grandi AM. New evidence on the potential role of the metabolic syndrome as a risk factor for venous thromboembolism. J Thromb Haemost 2009;7:736-8.
    1. Christiansen SC, Lijfering WM, Helmerhorst FM, Rosendaal FR, Cannegieter SC. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010;8:2159-68.
    1. Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, et al. Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism Trial. J Thromb Haemost 2006;4:2199-203.
    1. Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004;2:743-9.
    1. Le Gal G, Kovacs MJ, Carrier M, Do K, Kahn SR, Wells PS, et al. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode: data from the REVERSE Cohort Study. Thromb Haemost 2010;104:498-503.
    1. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(suppl 6):454-545S.
    1. Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995;74:606-11.
    1. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995;332:1661-5.
    1. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-8.
    1. Piovella F, Crippa L, Barone M, Vignanò D’Angelo S, Serafini S, Galli L, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002;87:515-22.
    1. Agnelli G, Becattini C, Prandoni P. Recurrent venous thromboembolism in men and women. N Engl J Med 2004;351:2015-8.
    1. Franzeck UK, Schalch I, Jager KA, Schneider E, Grimm J, Bollinger A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich Study). Circulation 1996;93:74-9.
    1. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-7.
    1. Oger E, Lacault K, Le Gal G, Couturaud F, Guénet D, Abalain JH, et al. Hyperhomocysteinemia and low vitamin B levels are independently associated with venous thromboembolism: results from the EDITH Study: a hospital-based case-control study. J Thromb Haemost 2006:4:793-9.
    1. Piccioli A, Lensing AWA, Prins MH, Falanga A, Scannapieco GL, Ieran M, et al, for the SOMIT Investigator Group. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004;2:884-9.
    1. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123(suppl 4):11-7S.
    1. Eichinger S, Kyrle PA. Duration of anticoagulation after initial idiopathic venous thrombosis—the swinging pendulum: risk assessment to predict recurrence. J Thromb Haemost 2009;7(suppl 1):291-5S.
    1. . Clinical decision rule validation study to predict low recurrent risk in patients with unprovoked venous thromboembolism (REVERSEII). 2011. .
    1. White RH. Epidemiology of venous thromboembolism. Circulation 2003;107(suppl 1):I4-8S.
    1. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005;3:1611-7.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться